SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Dog (Bitcoin) is a fully decentralized memecoin on the Bitcoin blockchain, backed by a community dedicated to onboarding millions of people to Bitcoin.  Dog is secured by the Bitcoin blockchain and exists on Bitcoin L1, marking a significant innovation compared to Bitcoin with just BTC. Dog is a Bitcoin Runes token with a minimal on-chain footprint, native to Bitcoin, and stored in UTXOs, just like Bitcoin.   What is the project about?  Dog does not do any paid promotion and is fully decentralized just like Bitcoin. Every influencer who chooses to post about Dog either received the airdrop or bought on secondary. Dog leverages the CC0 license to ensure that Dog is not owned by any single entity but rather by everyone. This had lead to the "DOG Army" independently creating art, apps, lotteries, plushies, websites, podcast, magazines, X account, IRL meetups, clothing lines, PFP collections, Telegram groups, and TikTok/Instagram about Dog.  What makes your project unique?  Dog was airdropped in the fairest memecoin launch ever. In early 2024, the Bitcoin Ordinals ecosystem came together in a full volunteer initiative that rewarded early adopters of the Ordinals Protocol. There was no team allocation, and 100% of the supply was airdropped for free. The airdrop algorithm favored neither whales nor influencers; it was determined by the community and made open-source for maximum transparency.

Dog (Bitcoin)

$DOG.X is trending as a Bitcoin-native meme coin launched via the Runes protocol, generating buzz for its fair distribution and strong community. Discussions highlight its potential to drive utility and transaction volume on the Bitcoin network, with many touting it as a leader in the current cycle. Community members are actively promoting its unique position compared to other meme coins and speculating about potential exchange listings.

Summit Therapeutics, Inc. is a biopharmaceutical company, that focuses on the discovery, development, and commercialization of patient, physician, caregiver, and societal-friendly medicinal therapies intended to improve quality of life, increase potential duration of life, and resolve serious unmet medical needs. The firm conducts clinical programs focusing on Clostridioides Difficile Infection (CDI). Its lead product, Ridinilazole, is an orally administered small molecule antibiotic that is in Phase III clinical trials for the treatment of CDI. The company was founded in 2003 and is headquartered in Miami, FL.

Summit Therapeutics Inc

Summit Therapeutics is trending amid speculation around a potential licensing deal with AstraZeneca, with community members discussing the impact of recent trial data and a possible buyout. Some investors are analyzing trial endpoints and revenue potential, while others are comparing SMMT to competitors like IOVA. The community is closely watching for further developments and official announcements.

ProShares Trust - ProShares Short Dow30 -1x Shares

ProShares Short Dow30

$DOG is trending as the Bitcoin memecoin gains traction within the crypto community, with many touting its fair launch and strong community backing. Conversation highlights its potential to become the meme face of Bitcoin and draw comparisons to other popular memecoins. Community members are emphasizing its organic growth and decentralized nature.

DOVU

DOVU.X is trending as the community highlights its staking rewards and potential in the Real World Asset (RWA) space, particularly due to its "Trust Operating System." Recent news around partnerships and deals related to carbon credits and ecological projects may be acting as a catalyst. Community members are actively discussing its association with Hedera and potential for significant growth.

Gyrodyne LLC engages in the management of a portfolio of medical office and industrial properties. Its properties include Flowerfield, Port Jefferson Professional Park, Courtland Medical Center, and Grove. The company was founded by Peter James Papadakos in 1946 and is headquartered in St. James, NY.

Gyrodyne LLC

GYRO is trending due to a significant land sale agreement, potentially boosting its NAV. The community is discussing the stock's low float and potential for a substantial price increase, with some highlighting potential squeeze dynamics. Bullish sentiment appears to be building, driven by the company's real estate assets and upcoming shareholder meeting.

K9 Finance, a Shibarium-based LSD platform, offers core DeFi services and acts as an official validator. Rewarding $KNINE holders with $BONE for block validation, it aims to drive DeFi adoption via the 'Roundtable of Dogs' DAO, which governs treasury and roadmap decisions.

K9 Finance DAO

K9 Finance DAO ($KNINE.X) is trending due to the upcoming K9 Quest Airdrop and its role as a key player in Shibarium's DeFi ecosystem, offering liquid staking for $BONE.X. The community is actively discussing staking strategies, DAO governance, and ways to earn rewards through Bonecrusher and ShibaSwap integration. With its innovative tri-token system and focus on real yield, K9 Finance is positioned to drive DeFi adoption on Shibarium.

Casey's General Stores, Inc. engages in the provision of management and operation of convenience stores and gasoline stations. It provides self-service gasoline, a wide selection of grocery items, and an array of freshly prepared food items. The firm offers food, beverages, tobacco products, health and beauty aids, automotive products, and other non-food items. The company was founded by Donald F. Lamberti in 1968 and is headquartered in Ankeny, IA.

Casey`s General Stores, Inc.

Casey's General Stores, Inc.

Casey's General Stores is trending following a strong earnings report, with community members discussing the impressive EPS figures. Bullish sentiment is fueled by solid inside and fuel margins, although revenue slightly missed expectations. The company's strategic focus on prepared foods and expansion plans are also key talking points.

Emergent BioSolutions Inc. engages in the development, manufacture, and commercialization of medical countermeasures. It offers products for civilian and military populations that address accidental, intentional, and naturally occurring public health threats. The firm's products include ACAM2000, BioThrax, Raxibacuma, Vaxchora, and VIGIV. Its business units include Vaccines and Anti-Infectives, Antibody Therapeutics, Devices, and Contract Development and Manufacturing. The company was founded by Fuad El-Hibri on September 5, 1998 and is headquartered in Gaithersburg, MD.

Emergent Biosolutions Inc

Emergent BioSolutions is trending due to confirmed new government orders for medical countermeasures, driving optimism about revenue and profitability. The community is actively discussing the potential for a short squeeze given the high short interest and upcoming investor conferences. Some investors speculate about a potential takeover, pointing to the company's cash position and strategic assets.

Chewy, Inc. operates as an online retailer of pet food and other pet-related products and services. It supplies pet medications, food, treats and other pet-health products and services for dogs, cats, fish, birds, small pets, horses, and reptiles. It has a portfolio of pet healthcare offerings that includes Chewy Pharmacy, Connect with a Vet, and CarePlus, an exclusive suite of pet-first insurance and wellness plans. The company was founded by Ryan Cohen and Michael Day in September 2011 and is headquartered in Plantation, FL.

Chewy Inc - Ordinary Shares - Class A

Chewy Inc

Chewy is trending as investors digest the latest earnings report and guidance, with community members actively discussing the company's market position and future growth prospects. While some express disappointment, others point to positive aspects of the report and reiterate long-term bullish sentiment, viewing any price drops as buying opportunities. Technical analysis and analyst ratings are also contributing to the ongoing conversation around $CHWY.

Intellia Therapeutics, Inc. is a clinical stage genome editing company, which engages in the development of curative therapeutics using the CRISPR/Cas9 system. Its CRISPR/Cas9 system transforms medicine by both producing therapeutics that permanently edit and/or correct disease-associated genes in the human body with a single treatment course, and creates engineered cells that can treat oncological and immunological diseases. The company was founded by Andrew May, Luciano Marraffini, Rodolphe Barrangou, Nessan Bermingham, Rachel Haurwitz, Erik Sontheimer, Jennifer Doudna, and Derrick Rossi in May 2014 and is headquartered in Cambridge, MA.

Intellia Therapeutics Inc

NTLA is trending amid discussions about its gene therapy pipeline and recent safety data from a Phase 3 trial; the community is weighing the long-term potential against short-term risks. Some traders are focusing on analyst ratings and potential for a sector rotation, while others discuss potential acquisition scenarios and ARK Invest's position in the stock. Overall, the conversation revolves around the balance between gene editing's promise and the volatility of clinical trials.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Compared to Estimates, Beazer (BZH) Q3 Earnings: A Look at Key Metrics

While the top- and bottom-line numbers for Beazer (BZH) give a sense of how the business performed in the quarter ended June 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Beazer Homes (BZH) Q3 Earnings and Revenues Lag Estimates

Beazer (BZH) delivered earnings and revenue surprises of -38.10% and -1.62%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Do Options Traders Know Something About Beazer Homes Stock We Don't?

Investors need to pay close attention to BZH stock based on the movements in the options market lately.

Earnings Preview: Beazer Homes (BZH) Q3 Earnings Expected to Decline

Beazer (BZH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Tri Pointe Homes (TPH) Beats Q2 Earnings and Revenue Estimates

Tri Pointe (TPH) delivered earnings and revenue surprises of +16.67% and +11.29%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Taylor Morrison Home (TMHC) Q2 Earnings and Revenues Beat Estimates

Taylor Morrison (TMHC) delivered earnings and revenue surprises of +4.12% and +3.35%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Beazer Homes Accelerates Pace of Share Repurchases

Beazer Homes USA, Inc. (NYSE: BZH) today announced that it is accelerating the pace of its share repurchases in light of recent share price dislocation. The Company will continue to repurchase shares...

Shares of Beazer Homes USA Inc. ($BZH) fell 10.65% in after-hours trading on Thursday after home builder missed EPS estimates in the first-quarter, &nbsp;but retail sentiment stayed neutral.Beazer posted $0.10 in earnings per share compared to $0.31 quoted by Wall Street analysts.However, the company’s revenues beat estimates, coming in at $468.95 million, above the $464.42 million that analysts expected. Its first quarter homebuilding revenue stood at $460.4 million, up 20.9% year-over-year. The increase was driven by a 22.1% increase in home closings to 907 homes.“Despite a challenging new home sales environment, we had a productive first quarter and made progress toward our full year and multi-year goals,” Allan P. Merrill, chairman and CEO of Beazer, said. “Net new orders and closings increased year-over-year, supported by a 20% higher community count. We also grew our total lot position by about 10% versus the prior year, primarily through options, positioning us for further community count growth in the years ahead.”Looking to the full fiscal year, Merill said that despite the affordability challenges of the near-term environment, the company is confident about a double-digit return on capital employed this year.Sentiment on Stocktwits stayed ‘neutral’ compared to a day ago. Message volumes were ‘extremely low’<figure class="image"><img style="aspect-ratio:1286/282;" src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/Screenshot_2025_01_31_at_10_55_15_AM_a619dc5289.png" alt="Screenshot 2025-01-31 at 10.55.15 AM.png" width="1286" height="282"><figcaption>BZH sentiment meter an message volumes on Jan 31 as of 1 am ET</figcaption></figure>At the end of the first quarter, Beazer had $335.4 million of available liquidity, including $80.4 million of unrestricted cash and $255.0 million of remaining capacity under the unsecured revolving credit facility.Beazer stock is up 1% year-to-date.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Beazer Homes Stock Slips On Q1 Earnings Miss: Retail Stays Cautious

Beazer posted $0.10 in earnings per share compared to $0.31 quoted by Wall Street analysts.

Equity

Beazer Homes Reports First Quarter Fiscal 2025 Results

Beazer Homes USA, Inc. (NYSE: BZH) (www.beazer.com) today announced its financial results for the three months ended December 31, 2024. Despite a challenging new home sales environment, we had a...

Beazer Homes USA, Inc. to Webcast Its Fiscal First Quarter Results Conference Call on Thursday, January 30, 2025

Beazer Homes (NYSE: BZH) (www.beazer.com) has scheduled the release of its financial results for the quarter ended December 31, 2024 on Thursday, January 30, 2025 after the close of the market...

Beazer Homes USA, Inc. engages in the design and sale of single-family and multi-family homes. It operates through the following geographical segments: West, East, and Southeast. The West segment includes Arizona, California, Nevada, and Texas. The East segment consists of Delaware, Indiana, Maryland, Tennessee, and Virginia. The Southeast segment focuses on the Florida, Georgia, North Carolina, and South Carolina. The company was founded in 1985 and is headquartered in Atlanta, GA.

BZH
Beazer Homes USA Inc.

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest BZH News

BZH Beazer Homes USA Inc.